DDX6 expression is elevated in patients with AML. (A) DDX6 mRNA expression across different cytogenetic subgroups of AML. Data from MILE study.⁶² Data are presented as mean log2 expression with range. ∗P < .05, ∗∗P < .01; Student t test. (B) DDX6 mRNA expression across different cytogenetic subgroups of AML.⁶³ Data are presented as mean log2 expression with range. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, and ∗∗∗∗P < .00001; unpaired Student t test. DDX6 mRNA expression from TCGA data sets across different cytogenetic subgroups of AML (C) and normal karyotype patients with CN-AML bearing different mutations (D). Data are presented as mean log2 expression with range. Unpaired Student t test. Kaplan-Meier curves showing the outcomes of patients with AML from the TCGA data set with high vs low expression of DDX6 in all patients (n = 150) (E), patients with complex karyotype (n = 18) (F), normal karyotype (CN-AML) (n = 60) (G), patients with CN-AML with NPM1 mutations (n = 33) (H), patients with CN-AML with FLT-ITD mutations (n = 18) (I), and patients with CN-AML with DNMT3A mutations (n = 24) (J). P value was calculated by log-rank test. inv, inverted; ns, not significant.